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Abstract
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Drug discovery is an extremely difficult and challenging endeavor with a very high failure rate.
The task of identifying a drug that is safe, selective and effective is a daunting proposition because
disease biology is complex and highly variable across patients. Metabolomics enables the
discovery of disease biomarkers, which provides insights into the molecular and metabolic basis of
disease and may be used to assess treatment prognosis and outcome. In this regard, metabolomics
has evolved to become an important component of the drug discovery process to resolve efficacy
and toxicity issues, and as a tool for precision medicine. A detailed description of an experimental
protocol is presented that outlines the application of NMR metabolomics to the drug discovery
pipeline. This includes: (1) target identification by understanding the metabolic dysregulation in
diseases, (2) predicting the mechanism of action of newly discovered or existing drug therapies,
(3) and using metabolomics to screen a chemical lead to assess biological activity. Unlike other
OMICS approaches, the metabolome is “fragile”, and may be negatively impacted by improper
sample collection, storage and extraction procedures. Similarly, biologically-irrelevant conclusions
may result from incorrect data collection, pre-processing or processing procedures, or the
erroneous use of univariate and multivariate statistical methods. These critical concerns are also
addressed in the protocol.
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17.For high throughput NMR data collection, please refer to the Bruker ICONNMR manual to explore various configuration options.
For example, composite experiments allow for the collection of multiple 1D and 2D experiments for the same metabolomics sample.
An experimental set consisting of a 1D 1H, a 2D 1H-13C HSQC, and 2D 1H-13C HMBC experiment may be subsequently collected
for the same sample before moving to the next sample in the queue.
18.It is imperative that NMR data are collected at the same temperature for a queue of metabolomics samples. ICONNMR assists this
by allowing for a temperature delay when a large number of samples are in the SampleJet queue. For example, a 15 to 60 second delay
may be inserted prior to data acquisition to allow each sample to equilibrate to the probe temperature. We recommend a 60 second
delay for both pre- and post-sample insertion to prevent any temperature variation.
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Introduction
Nuclear Magnetic Resonance (NMR) spectroscopy is an instrument of choice for drug
discovery and design (see Fig. 1) [1,2]. For decades, NMR has provided structural details for
druggable protein targets, and is routinely used for investigating protein-drug interactions
and conducting high-throughput ligand-affinity screens. In this regards, NMR is able to
obtain atomic-level resolution of protein-ligand structures in near physiological conditions
that results in better quality chemical leads [3,4]. Accordingly, NMR has enhanced the
success rate of the drug discovery process and has made numerous contributions to the
development of new therapeutics [5-7]. In addition to its role in structural biology, NMR has
also made significant contributions to the field of metabolomics, especially in the application
of metabolomics to drug discovery [8-12].
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A traditional view of a disease is as a genome or proteome level dysfunction, but there is a
growing appreciation for the role of metabolomic perturbations in a variety of human
diseases [13]. For example, an alteration in glucose metabolism is a well-known hallmark of
cancer (i.e., Warburg effect), but other metabolic changes are also associated with cancer,
such as glutaminolysis, redox imbalance, and flux changes in the tricarboxylic acid (TCA)
cycle or the pentose phosphate pathway (PPP). [14]. Similarly, antibiotic resistance in
Staphylococcus aureus has been shown to result from a re-direction of carbon flow into
metabolic processes that counter-act antibiotic activity [15,16]. Another example is
mitochondrial metabolism, especially changes in NAD levels, which is an indicator of aging
and age-related disorders [17]. The NAD-sirtuin pathway regulates neuronal protection and
is an important process that prevents axon degradation, which is a primary cause of
Parkinson’s disease and Alzheimer. Thus, lowered NAD+ levels is a crucial metabolic
observation in neurodegeneration that is being manipulated for disease prevention [15,17].
Thus, the characterization of metabolite levels in any biological system coupled with the
ability to trace the metabolic fate of individual atoms has the potential to beneficially impact
a variety of biomedical needs [12]. Specifically, metabolomics is an invaluable tool of drug
discovery, since metabolic changes may be used to identify therapeutic targets, verify in vivo
drug efficacy, decipher mechanisms of action, and identify potential toxic side-effects.

Author Manuscript

The drug discovery pipeline is an extremely resource intensive endeavor. The process is
time-consuming and may require upwards of twelve years before a new drug obtains FDA
approval [18]; and costly, with an average expense of $2.6 billion dollars per approved drug
[19]. The process is also prone to a very high failure rate where only a few lead compounds
that emerge from traditional medicinal chemistry efforts can be transferred to clinical trials
[20]. Furthermore, very few drug leads make it past Phase I clinical trials, and most
compounds eventually fail in Phase III [21]. On average, less than one-in-ten compounds
receive FDA approval and are launched as a new drug entities [22]. Of course, FDA
approved drugs are still routinely pulled from the market or encounter safety concerns when
broadly prescribed [23]. This low overall success rate is a result of numerous problems
routinely encountered throughout the drug discovery process [24,25]. These problems are
multifactorial, complex in nature, disease specific, and, in some cases, poorly understood;
they have also been extensively discussed and reviewed in the literature [26-31].
Accordingly, it is well-appreciated that a single technological advancement is not going to
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resolve the entirety of the challenges facing drug discovery research, but a new approach
may lead to better chemical leads, to a reduction in toxicity issues, or an improvement in
selectivity and efficacy. Thus, incorporating NMR metabolomics into a standard drug
discovery pipeline may lead to an improved success rate, but it won’t solve all of the field’s
problems.

Author Manuscript

Metabolomics has the potential to identify therapeutic targets in the drug discovery process.
First, metabolomics may improve our fundamental understanding of cellular physiology,
disease development or disease progression, which may lead to the discovery of new
therapeutic targets. In addition, metabolic profiles resulting from a disease state or drugresistance may identify cellular or metabolic processes that are critical to the system. In this
manner, specific proteins associated with these up-regulated or down-regulated pathways
may be targeted in either a single drug therapy or as part of a multi-drug treatment. The
underlying assumption is that the perturbed metabolic processes are required to maintain the
drug resistance or disease state. Accordingly, inhibiting these proteins may reverse the drugresistance or eliminate the disease. Of course, the metabolic profile of a disease state may
also be used to monitor a response to treatment [32]. The return of the metabolic profile to a
healthy state would be indicative of a positive therapeutic response. Similarly, a lack of a
response would suggest an ineffective treatment, and, conversely, a drastic change in the
metabolic profile may be indicative of a toxic response. Thus, in total, metabolomics may
beneficially impact all the steps of the drug discovery process, from target identification to
therapeutic monitoring.
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Cancer biology has pioneered the idea of metabolic dysregulation as the source of disease
pathology. Warburg aerobic glycolysis and glutaminolysis are essential features of cancer
pathogenesis and are known to occur in most tumors [33]. These metabolic processes are
potentially linked to oncogene and tumor suppressor regulation [34]. Thus, new therapeutic
targets to improve cancer management may be based on modulating these altered metabolic
processes. For example, a new experimental treatment for cancer is 4-phenylbutyrate [35],
which is a sacrificial metabolite that induces an alternative metabolic pathway to overcome a
defective urea cycle and repair a nitrogen imbalance. Presumably, 4-phenylbutyrate may
indirectly address a dysregulated glutaminolysis by facilitating the excretion of glutamine in
the urine [36]. Specifically, 4-phenylbutyrate is converted to 4-phenylacetate, which then
reacts with glutamine to form the excretion product phenylacetylglutamine.
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In a similar manner, on-going efforts to develop novel cancer treatments by targeting
metabolic dysregulation (e.g., glycolysis, glutaminolysis, PPP) has highlighted the
therapeutic importance of metabolic enzymes such as pyruvate dehydrogenase kinase,
lactate dehydrogenase A, glutaminase 1, thioredoxin reductase and gamma glutamylcysteine
synthetase [37,38]. In fact, inhibitors developed against all of these metabolic targets are
currently at various stages of preclinical and clinical trials. Indeed, anti-metabolite
compounds and enzyme inhibitors are among the most commonly prescribed drugs. For
example, gemcitabine, a first-line treatment for pancreatic cancer, is a nucleotide
(metabolite) analog that interferes with DNA synthesis [34]. Notably, gemcitabine resistance
results from a metabolic shift that increases the cellular production of deoxycytidine
triphosphate to function as a competitive inhibitor of gemcitabine [34]. Similarly,
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azathioprine is a purine analog that disrupts RNA and DNA synthesis and is used to treat
autoimmune diseases like Crohn’s disease and rheumatoid arthritis [39]. Sulfanilamide
antibiotics inhibit bacterial enzymes that require para-aminobenzoic acid (PABA) for
synthesizing folic acid, a coenzyme in DNA synthesis. Treatments for inborn errors of
metabolism are other successful examples of employing metabolite analogs as a therapy
[40]. Clearly, a metabolic view of disease pathology has beneficially contributed to existing
drugs and the creation of next generation therapies; and has the potential of significantly
improving patient outcomes [41].
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As illustrated above, NMR-based metabolomics is an asset for drug discovery since it helps
characterize metabolite level perturbations and altered metabolic pathways that may be used
to identify protein targets for designing new drugs. NMR is also routinely used as a highthroughput screen to identify and evolve chemical leads against these protein targets. NMR
ligand-affinity screens such as SAR-by-NMR, MS/NMR, multi-step NMR, SHAPES, and
FAST-NMR that make use of saturation transfer difference (STD), WaterLOGSY, 19F NMR,
HSQC chemical shift perturbations (CSP), transfer NOEs, and fragment-based libraries are
established means of identifying and validating chemical leads through experimentallyobserved protein-ligand interactions [42-47]. Consequently, combining NMR HTS
techniques with metabolomics to implement a high content drug screen is a logical next step.
One such example is the NMR-based metabolomics screen of a library of 56 kinase
inhibitors targeting eEF-2 kinase and NF-kB [48]. Tiziani et al. monitored global metabolic
changes resulting from compound treatment to a panel of cancer cell lines (e.g., HeLa,
CCRF-CEM, SKOV-3, and acute myeloid leukemia (AML) primary cells) in a 96-well
format. SDS induced cell lysates were then used to collect one-dimensional (1D) 1H CPMG
and two-dimensional (2D) 1H JRES NMR spectra followed by multivariate statistical
analysis of the entire spectral dataset. The resulting scores and backscaled loadings plot
calculated relative to controls were used identify active lead compounds based on the
magnitude of the metabolic response. Notably, approximately 100 samples were screened in
less than 24 h.

Author Manuscript

NMR metabolomics combined with traditional medicinal chemistry can, thus, be used to
validate in vitro efficacy, selectivity, and specificity while avoiding off target effects (see Fig.
2). Metabolic perturbations resulting from a drug treatment may be correlated to the
inhibition of the desired protein-target and/or as a result of unexpected off-target effects
[49]. If the lead compound inhibits additional protein targets beside the specifically designed
drug-target, then the lack of selectivity may help predict and anticipate toxicity issues in
future clinical trials. Thus, medicinal chemistry techniques can then be used to evolve the
chemical lead in an iterative fashion using insights and feedback from the metabolomics
experiments. The goal is to maintain the metabolic profile associated with inhibiting the
desired protein target while diminishing or eliminating metabolic changes resulting from
unwanted off-target effects. This global approach of monitoring all possible changes to the
system in response to a drug’s activity would be difficult, if not impossible, to replicate in an
in vitro setting. Even if the specific off-target proteins could be identified, it is not feasible to
reproduce the synergistic and simultaneous impact on multiple cellular processes.
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In a similar manner, an in vivo mechanism of action for a new chemical lead may be inferred
by comparing its induced metabolic profile against metabolic profiles for drugs with known
mechanisms of action [50]. Compounds that share the same mechanisms of action would be
expected to have similar impacts on the metabolome. Technological advances have reduced
NMR analyses times to less than a few mins per sample [51]. Thus, like other secondaryassays routinely used in a drug discovery pipeline, metabolomics can be applied in a highthroughput fashion to interrogate an entire library of chemical leads. Accordingly,
metabolomics is a cost-effective means of filtering-out problematic lead compounds prior to
expensive clinical trials.
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Mechanistic understanding of in vivo drug activity is an important, and, typically,
challenging stage of the drug discovery process. Knowledge of in vitro and in vivo
mechanisms of action improves the overall success rate and will beneficially enhance the
drug design effort [50]. Unfortunately, elucidating a mechanism of action for a specific
chemical lead may be an arduous, time-intensive and resource-intensive task. Multiplying
this effort across a large screening library is impractical. Instead, predicting the in vivo
mechanism of action for new chemical leads by leveraging known entities is a valuable
alternative to resolving this problem. Furthermore, the availability of a set of drugs with a
diverse range of biological activities for such a comparison will increase the likelihood of
successfully assigning a mechanism of action. In addition, identifying compounds that target
various biological processes and have a range of mechanisms of action may also assist in
disease management and in combating the emergence of resistance. This may be
accomplished through a multidrug therapy that combines compounds with distinct modes of
action. Halouska et al. [50] demonstrated the general approach by comparing the metabolic
profile of Mycobacterium smegmatis following treatment with a range of antibiotics with
known mechanisms of action and some promising chemical leads from high-throughput cellbased screens. 1D 1H NMR spectra combined with multivariate analysis was used to
characterize the relative global metabolomes. As expected, antibiotics with similar modes of
action clustered together in the orthogonal projections to latent structures (OPLS) scores
plot. The high throughput screening (HTS) chemical leads clustered together with known
cell wall inhibitors implying a similar mechanism of action, which was supported by
literature reports. It is also possible to invert the protocol and use a drug with a known
mechanism of action to modulate a metabolic pathway predicted to be important to disease
progression of drug-resistance. In this manner, if the targeted metabolic pathway is reversed
following drug treatment and the desired therapeutic outcome is achieved (i.e., cell death)
then an in vivo mechanism of action is likely indicated. A recent example of this process
involved a vancomycin intermediate resistant strain of staphylococcus aureus (VISA) that
exhibited an increase in purine biosynthesis relative to a vancomycin-susceptible strain
(VSSA) [15]. Treating VISA strains with a combination drug therapy consisting of a sub
lethal dose of vancomycin and 6-mercaptopurine (i.e., purine substrate analog) led to a
statistically significant increase in staphylococcal killing. In addition to reversing the
acquired vancomycin resistance, the metabolomics results also indicate (as expected) that
the in vivo mechanism of action for 6-mercaptopurine is an inhibitor of purine biosynthesis.
Metabolomics can also provide valuable information during a clinical trial. Metabolomics
can assist with therapeutic monitoring, drug dosage adjustments, and by differentiating
Methods Mol Biol. Author manuscript; available in PMC 2020 February 17.
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responders from non-responders. Simply, specific metabolic profiles may be attributed to
each group, which then can be used to classify individual patients by monitoring metabolite
changes in common biofluids such as urine, serum or fecal material. Another aspect of a
clinical trial that has benefited from metabolomics is monitoring patient compliance. In this
regards, patient non-compliance is readily identified by the presence of distinct and/or strong
signals in the NMR spectrum that are not normally present, such as metabolites from drug
metabolism or from consuming of caffeine, ethanol or nicotine. As a result of these clear
benefits to drug discovery, metabolomics continues to be adopted by the pharmaceutical and
biotechnology industry. A prime example is COMET, the COnsortium of MEtabonomic
Toxicity [52], which brought together pharmaceutical companies to utilize large datasets of
NMR metabolomics analysis of urine and serum samples to predict drug toxicity.
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To address the expanding interest in NMR metabolomics, we present a detailed, step-by-step
description of a metabolomics workflow with a specific attention to details important to its
application to a drug discovery and design process. The protocol includes methods relevant
to understanding the mechanism of action of novel drug leads in comparison to existing
therapeutics. Furthermore, we describe the application of metabolomics to wide-variety of
sample sources commonly encountered in drug discovery programs. This includes bacterial
and mammalian cell cultures, human and animal tissue samples and different biofluids (e.g.,
urine, serum and fecal material). The entire process from cell culturing and sample
collection to biological interpretation is described. Importantly, the protocol addresses
critical concerns regarding the proper: (i) preparation and handling of metabolomics
samples, (ii) pre-processing, processing and acquisition of spectral data, (iii) metabolite
identification, and (iv) statistical analysis.
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Unlike other OMICS techniques, the composition of the metabolome can easily change from
the processing, handling, and storage of samples [53]. Metabolites are chemically labile or
unstable, are subject to thermal degradation or oxidation, and are readily transformed by
residual enzymatic activity. For example, the oxidation of cysteine and glutathione, or the
conversion of ATP to AMP (because of a labile phosphate group) are common occurrences
in metabolomics samples [54]. These biologically-irrelevant sample variations may distort
our understanding of a system and lead to erroneous conclusions. Accordingly,
metabolomics requires a robust, efficient, and fast workflow to yield reproducible and
reliable data. Univariate and multivariate statistical analyses are essential components of any
metabolomics study and provide the means to interpret the data set and identify the key
group variances (i.e., metabolite changes) [55]. Nevertheless, issues such as the incorrect
application of statistical techniques, the subsequent lack of proper model validation, or the
over-interpretation of models are a common occurrence in the field of metabolomics [56].
Accordingly, the protocol presented herein addresses these issues by providing instructions
to avoid common mistakes.

Author Manuscript

2.

Materials
All samples should be prepared using Nanopure water (H2O) and/or deuterated water (D2O).
All safety regulations should be followed for the proper handling and disposal of chemicals
and biological samples used in the study.
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Laboratory Equipment
1.

Bruker AVANCE III HD 700 MHz NMR spectrometer equipped with a 5 mm
quadruple resonance QCI-P cryoprobe (1H, 13C, 15N, and 31P) with z-axis
gradients, an automatic tune and match system (ATM), and a SampleJet
automated sample changer system with Bruker ICON-NMR software (Bruker
Biospin, Billerica, MA).

2.

BSL-2 biosafety level grade hood (e.g., Biological Safety Cabinet, LF BSC class
2 type A, Thermo Fischer Scientific, Waltham, MA).

3.

Nanopure ultra water system (Barnstead Inc., Dubuque, IA).

4.

Lab Armor bead bath (Chemglass Life Sciences, Vineland NJ).

5.

Incubator capable of maintaining physiological temperature and proper carbon
dioxide levels (e.g., HERA CELL VIOS 250i CO2 Incubator, Thermo Fischer
Scientific, Waltham, MA).

6.

pH meter and probe.

7.

Refrigerated centrifuge capable of speeds up to 21,100 g (e.g., SORVALL micro
21R centrifuge, Thermo Fischer Scientific, Waltham, MA).

8.

Speed Vac for solvent removal (e.g., SAVANT SC210A SpeedVac concentrator,
Thermo Fischer Scientific, Waltham, MA).

9.

Freeze dryer to remove water (e.g., FreeZone 4.5, LABCONCO, Kansas City,
MO).

10.

1 μL to 1000 μL pipettes

11.

FastPrep-96 homogenizer (MP Biomedicals, Santa Ana, CA).

12.

ACCU-SCOPE 3030ph microscope (Commac, NY).

13.

Cryogenic storage container (Taylor Wharton, Theodor, Al).

14.

−80 °C freezer.

15.

Flask shaker incubator (up to 250 rpm).

16.

Sonic Dismembrator (Sonicator).

Disposable supplies

Author Manuscript

1.

1 μL to 1 mL pipette tips.

2.

10 mL aspirating pipettes.

3.

15 mL Falcon tubes.

4.

2 mL Eppendorf tubes.

5.

1 mL screw-cap microcenterfuge tubes.
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1.

Deuterium oxide (D2O, 99.8 atom %D).

2.

3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TMSP-d4, 99.8 atom %
D).

3.

Dimethyl sulfoxide-d6 (DMSO-d6, 99.8 atom %D).

4.

13C

5.

13C

6.

Other potential 13C-carbon labeled or 15N-nitrogen labeled reagents.

1.

Wash buffer, phosphate-buffered saline (PBS) at pH 7.4: 137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4 and 2 mM KH2PO4. To prepare 1 L PBS buffer at pH
7.4, add 8.0 g of NaCl, 0.2 g of KCl, 2.68 g of Na2HPO4.7H20 and 0.24 g of
KH2PO4 to a final volume of 1 L of Nanopure water.

2.

NMR buffer: 50 mM phosphate buffer at pH 7.2 (uncorrected, see Note 3) in 600
μL of 99.8% D2O. Add 50 μM (1D NMR experiment) or 500 μM (2D NMR
experiment) TMSP-d4 as an internal chemical shift reference.

6-glucose

2-acetate

(99% 13C).

(99% 13C).

Buffers

Cell Media (see Note 4)
1.

Dulbecco’s modified eagle medium (DMEM) and Roswell Park Memorial
Institute (RPMI) medium with the addition of an appropriate amount of fetal
bovine serum (5 to 20% v/v) and/or supplemental glucose (1 to 25 mM) are
commonly used to culture mammalian cells.

2.

Bacterial cells are typically cultured in complex media, such as like LuriaBertani (LB) media for E.coli, Middlebrook’s albumin dextrose catalase media
(MADC) for Mycobacterium smegmatis, or M9 minimal media.

Software and Databases
1.

Bruker ICON-NMR software for automated NMR data acquisition (Bruker
Biospin, Billerica, MA).

2.

MVAPACK metabolomics toolkit for processing and analyzing chemometric
data (http://bionmr.unl.edu/mvapack.php) [57].

Author Manuscript

1.NMR isotope labeled compounds are non-radioactive and do not require any special handling. It is imperative you wear typical
personal protective gear like gloves and eye protection and follow standard safety protocols.
2.Always keep deuterated solvents in a desiccator or dry box and keep them sealed or wrapped in parafilm while in storage.
3.Typically, metabolomics sample from cell lysates are prepared in 100% D O and using a standard pH probe may not report pH
2
accurately. Standard corrections are pD = pH + 0.4 although Rubinson et al. [92] suggest that phosphate buffer pH is not significantly
altered to warrant corrections.
4.The choice of culture medium is dependent on the specific needs of the cell type and the specific goals of the experiment. There are
a variety of cell culture media available either through commercial sources or from published recipes. Also, it may be possible to use
different media for the same cell type. Again, the choice of medium will be dictated by the specific needs of the experiment.
Accordingly, only a few representative culture media are listed as illustrative examples, and these are not intended to be an exhaustive
list.
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3.

PCA/PLS-DA utilities for quantifying separation in PCA, PLS-DA and OPLSDA scores plots (http://bionmr.unl.edu/pca-utils.php) [58].

4.

NMRPipe software for processing and visualizing NMR data (https://
www.ibbr.umd.edu/nmrpipe/install.html) [59].

5.

NMRViewJ software for processing and visualizing NMR data (One Moon
Scientific, Inc. Westfield, NJ; https://nmrfx.org/) [60].

6.

R statistical package (https://www.r-project.org/) [44].

7.

Chenomx (Chenomx, Inc., Edmonton, AB, Canada) software for automated
metabolite assignment and quantification from 1D 1H NMR spectra (https://
www.chenomx.com/).

8.

MetaboAnalyst software for the statistical, functional and integrative analysis of
metabolomics data (http://www.metaboanalyst.ca/) [61].

9.

Human Metabolomics Database (HMDB) of reference NMR data for known
metabolites (http://www.hmdb.ca/) [62].

10.

Biological Magnetic Resonance Data Bank (BMRB) of reference NMR data for
known metabolites http://www.bmrb.wisc.edu/metabolomics/) [63].

11.

Non-uniform schedule (NUS) generator (http://bionmr.unl.edu/dgsgensched.php) for NUS NMR data acquisition [64].

12.

Small Molecule Pathway Database (SMPDB) (http://www.smpdb.ca) for
modeling metabolic pathway changes from list of metabolite changes [65].

Methods
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Extreme consistency is key to the success of any metabolomics experiment. Accordingly, it
is essential to apply all experimental protocols and parameters uniformly to all groups in the
study. Any variation in the preparation, handling or storage of the sample may perturb the
metabolome and lead to an erroneous results. For example, different sample processing
times, samples handled by different investigators, cell cultures grown in different incubators
or shakers, different sources or lot numbers of chemicals, media or disposables, different
buffer/media preparations (even if the same recipe was prepared by the same individual), are
all likely to induce a biologically irrelevant-bias in the samples and needs to be avoided. In
effect, the only difference between groups should be the intended variable (e.g., wild-type
vs. mutant; treated vs. untreated, healthy vs. disease, etc.). In general, the defined variable(s)
is expected to induce a measurable change in the metabolome that is detectable by NMR.
For example, a proper dosage for a drug used in a metabolomics project needs to be
experimentally determined. The drug dosage needs to be high enough to induce a detectable
metabolic response, but not too high to induce a generic cell death phenotype (see Note 5).

5.For the success of a metabolomics experiment, cell survival is an essential requirement. This presents a challenge when investigating
the efficacy, side-effects, mechanism of action or resistance of a drug that impacts cell survival or is designed to kill cells. Similarly,
cell mutations or experimental conditions (e.g., nutrient depletion, high temperature, anaerobic growth, etc.) that may lead to an
increase in cell death are also potential problems. The goal is to identify a drug dosage and/or experimental condition that only stress
the cells, but does not result in any cell death (see section 3.3). In this regard, the observed metabolomic changes will only be a result
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Experimental Design
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A scientific hypothesis needs to be clearly defined in order to properly design a
metabolomics experiment (see Fig. 3). In other words, simply characterizing the
metabolome of a cell, tissue or biofluid is likely to fail to provide any scientific insight or
value without a logically designed comparative analysis. In this regards, a metabolomics
experiment is fundamentally a comparison between two or more groups (e.g., control vs.
drug treated), where a difference or similarity in a metabolome is expected to answer a
scientific question. The next critical step is to identify an appropriate source for the
metabolome or the type of biological samples to be compared (i.e., established or primary
cell lines, tissue samples from an animal model, or human biofluids, etc.). The choice of
system will then determine the number of biological replicates that can be practically
obtained, which, in turn, will define the statistical significance of any observed results.
Given a testable hypothesis and the type of biological samples, there are essentially an
endless number of experimental variables that can be manipulated, where each permutation
defines a new group. Practically speaking, it would be impossible to account for every
possible permutation in a single experimental design. Instead, the identification of which
groups to use is fundamentally driven by the scientific question the study is designed to
answer (see Fig. 3) Thus, a general set of protocols is presented for a generic metabolomics
experiment that can be applied to a drug discovery project. The protocol provides a means to
determine a drug’s mechanism of action and to monitor a patient’s response to treatment.
The simplest experimental design for a metabolomics drug discovery project will consist of
two groups: untreated samples and drug-treated samples. Nevertheless, it is typical to
significantly expand the experimental design beyond just two groups (see Figs. 2 and 3).
Common groups include:

Author Manuscript
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1.

Controls (e.g., wild type cells or healthy subjects).

2.

Control with treatment (positive control e.g., wild type cells or healthy animals
treated with a drug lead).

3.

Experimental model (e.g., animal disease model or treatment naïve patients).

4.

Experimental model with a drug treatment (e.g., animal disease model or patients
treated with a drug lead).

5.

Negative control (e.g., mutant cells with no treatment, patients with alternative
disease).

6.

Negative control with a drug treatment (e.g., mutant cell lines treated with a drug
lead).

The metabolomics study may consist of any combination of biological samples originating
from cell cultures, tissue samples and/or biofluids. Human or animal biofluids may consist
of urine, serum, plasma, blood, fecal material, saliva, sweat, condensed breath, cerebrospinal

of the cell’s immediate response to the biological activity of the drug or the experimental condition. Conversely, if the metabolome is
harvested from a mixture of live and dead cells, then it will be difficult, if not impossible, to deconvolute metabolome changes
resulting from the stressor or cell death. A correct drug dosage or experimental condition is usually determined by acquiring a series of
growth curves in which the drug or stressor is titrated over a wide-range of values.
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fluid (CSF) or any other body fluid or excretion. Similarly, tissue samples usually consist of
organs, such as heart, lungs, brain, liver or kidneys from sacrificed animals. Tissue samples
from human subjects typically originate from biopsies (i.e., muscle, adipose, etc.), from
surgeries (i.e., tumors) or tissue banks. Each biofluid, tissue type, or time-point would
constitute a different group. Of course, there are numerous experimental protocols that could
also be varied, such as different media, nutrients, temperature, diets, etc.

Author Manuscript

Besides sample type and experimental protocols, there are other variations that may be
applied to form additional groups. For example, different groups may be formed by varying
the drug dosage or by using a placebo. Of course, multiple drugs could be tested in a single
study and group membership would be defined by what drug a cell culture or an individual
receives. In addition, the number of drug treatments received by a cohort could vary. Time
could be another variable in the experimental design (e.g., when samples are collected and
when treatments are administered). Similarly, different groups may consist of different
mutant or wild-type cell lines or strains. For example, a mutant cell line may correspond to
the drug protein target being inactivated (i.e., negative control) through a variety of genetic
mutations or gene-knockout methods. Alternatively, the mutant cell lines could be various
human isolates with variable levels of resistance or susceptibility to the tested drug. The cell
lines could just be different types of bacteria (e.g., E. coli., S. aureus, etc.) or different types
of cancers (e.g., pancreatic, breast, etc.). Similarly, animal models or human cohorts may
have different stages or severity of the disease, or even different diseases. Furthermore,
multiple biofluid samples (i.e., both urine and serum) may be collected from the same
animal or human participant at multiple time points during the study. Similarly, more than
one tissue or organ sample may be harvested from each sacrificed animal.

Author Manuscript
Author Manuscript

Another important decision regarding the experimental design is the number of biological
replicates required per group. In general, more biological replicates led to a better statistical
significance in differentiating between the various groups. But of course, there are practical
limits to the number of cell cultures, animals or human cohorts that can be prepared or
recruited for any study. Facility and equipment capacities, the availability of personnel, and
cost, are all major factors that greatly limit the number of samples or cohorts that are
possible. There is also an obvious multiplication factor based on the number of desired
groups and the number of replicates per group. Accordingly, there may be a tendency to
maximize the number of groups at the expense of the number of replicates per group. This is
inadvisable since it would likely lead to statistically insignificant conclusions. Instead, the
number of groups should be reduced to achieve an acceptable minimal number of biological
replicates per group. In fact, sample size calculation for metabolomics studies is complex
and not well-defined, where recent efforts suggest sample sizes may need to be > 20 per
group [66,67]. In the case of metabolomics studies involving human cohorts, the need for
replicates is even greater and more challenging to estimate, but sample sizes > 60 to 100
cohorts per group are typical targets.
One final factor to consider for the design of a metabolomics study involving human cohorts
is the inclusion and exclusion criteria. Simply, what individual characteristics, traits or
behavior are needed for the goals of the study? Conversely, what are the potential
confounding factors that may confuse or obscure the desired outcome of the study and
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should be avoided? The specific inclusion and exclusion criteria are likely unique to each
study; and there are no general guidelines to apply. Criteria commonly considered include:
age, body mass index, diet, comorbidities, ethnicity, gender, health test panel (e.g., blood
pressure, lipid panel, metabolic panel, urinalysis, etc.), physical activity, race, and the use of
alcohol, recreational drugs, or tobacco (see Table 1).
3.2

Determining Drug Dosage for Cultured Cells

Author Manuscript

The reported minimum inhibitory concentration (MIC) for a drug against a specific cell
strain is a good starting point for determining the optimal drug dosage for a metabolomics
study. Typically, drug concentrations that range between 1 to 24 times the reported MIC or
MIC50 are tested to identify an optimal drug dosage. The goal is to identify a drug dosage
that stresses the cells, but does not induce cell death. This is accomplished by identifying a
drug dosage that results in a decrease in cell growth by approximately 50% (MIC50, see Fig.
4).
Along with dosage, the time point for administering the drug needs to be experimentally
determined. First, enough biomass needs to be harvested in order to extract a detectable
metabolome. Second, the timing of the drug dosage should induce the desired perturbation
in the metabolome. For example, a particular metabolic processes may only be active during
a specific phase of the growth curve. Typically, a drug treatment is administered during the
exponential or log phase for a bacterial culture. The cells are allowed to grow for at least one
generation or one doubling time before harvesting.

Author Manuscript
Author Manuscript

1.

Approximately 1 to 20 mM of a stock solution is prepared for each compound to
be tested by dissolving the required amount of the compound into 0.5 mL of
ethanol or DMSO-d6 (see Note 6).

2.

Bacterial cells are typically grown at 37 °C with shaking at 200 rpm in 50 mL of
complex or minimal media in a 125 mL Erlenmeyer flask. Mammalian cells are
typically grown in a 6 well plate with 3 mL of media at 37 °C and 5% percent
CO2 in an incubator. A total of 21 cell cultures are prepared.

3.

The bacterial cells are allowed to grow until an average optical density at 600 nm
(OD600) of 0.6 is achieved (see Fig. 4). Mammalian cells are grown to
approximately 40% confluency.

4.

Each cell culture receives a different aliquot of the stock drug solution such that
the final drug concentration ranges from 0 to 24 times the MIC value. Each drug
dosage is made in triplicate for a total of 21 cell cultures (see Note 7).

5.

Following the addition of the drug-leads, the cells are allowed to grow for an
additional amount of time. This is typically the cell doubling time.

6.The choice of solvent and concentration is determined by the compound’s solubility. The goal is to maximize the concentration of
the stock solution so as to minimize the amount of solvent that needs to be added to each cell culture. The maximal amount of solvent
added to a cell culture is 5 to 10 μL.
7.The following range of drug concentrations is typically used: 0x,1x, 2x, 4x, 8x, 16x and 24x the MIC value. The amount of solvent
(i.e., DMSO-d6 or ethanol) added to any cell culture should be 5 to 10 μL or less.
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For bacterial cells, the optical density (OD600) is recorded at the end of the
additional cell growth time. The growth rate inhibition is calculated by
comparing the optical density of the treated cells to the untreated cells. Typically,
untreated cells will reach an OD600 of 1.2 (i.e., a doubling from an initial OD600
of 0.6), while the OD600 of drug treated cells will be lower. For mammalian cells,
the cells are visualized under a microscope to measure the percent confluency
and assess the amount of detached cells [53,68,69]. Typically, untreated cells
should reach a confluency of approximately 80% (i.e., doubling from an initial
40% confluency).

7.

The desired dosage corresponds to the drug concentration that inhibits cell
growth by approximately 50% relative to untreated cells (see Note 5).

8.

For mammalian cells, an additional consideration is the length of time following
the drug treatment that is required before the cells can be harvested. It is
important to provide a significant amount of time to allow a perturbation in the
metabolome to occur, but it should be short enough to prevent a significant
accumulation of dead cells. No dead cells are a preferred outcome. After the
proper drug dosage is identified, repeat experimental steps 2 to 5 with the
following modifications:

Author Manuscript

6.

Author Manuscript
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9.

3.3

a.

A constant drug dosage is used for each replicate cell culture. Each cell
culture replicate is a different time-point instead of a different drug
dosage.

b.

The time after drug treatment that the cells are harvested are varied
from zero (i.e., control) to an end-point of approximately 12 to 24 h.

For each time point, the percentage of live and dead cells is determined with a
cell counter. The optimal time point for harvesting the cells would be the latest
time point following the drug treatment where the vast majority of the cells are
still alive.

Determining Drug Dosage for Cohorts.

Author Manuscript

How a drug is administered (e.g., oral, intravenous, intraperitoneal, etc.), how often the drug
is administered, how the drug is formulated, and the drug’s dosage will all impact how the
drug is adsorbed, distributed, metabolized and excreted (ADME) in an animal or human
[70,71]. This, in turn, will determine both the peak and steady-state concentration of the
drug; and the resulting efficacy and toxicity of the treatment. Determining the proper drug
dosage and the route of administering a drug lead for an animal model or a clinical trial is,
thus, a complex question that is not easily answered. In fact, the entire field of
pharmacokinetics and pharmacodynamics is dedicated to addressing these very challenging
questions [72]. Available information, such as a lethal dose (LD50) from cell based assays or
reported dosages for similar compounds from the scientific literature, may provide initial
guidance. Unfortunately, there is not a simple algorithm to convert an LD50 to an animal
dosage. Instead, a detailed efficacy and toxicity study needs to be conducted to determine
the proper drug dosage prior to embarking on a metabolomics study.
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Drug dosages are typically administered according to a species’ body-mass (e.g., mg/kg).
Accordingly, it may appear trivial to translate an animal drug dosage to a human clinical trial
by simply scaling the dosage based on relative body-masses. Unfortunately, this approach is
incorrect since pharmacokinetics and toxicity issues vary widely across species. Instead, a
variety of factors, such as differences in allometry, metabolic rates, and physiological, need
to be considered [73,74]. Thus, the protocol for determining the proper dose and means of
administering a drug candidate is beyond the intended scope of this chapter.
3.4

Author Manuscript
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3.5

Collecting and Storage of Biofluids from Human Cohorts (see Table 1)
1.

Human volunteers in a metabolomics study must sign an informed consent form
before participating.

2.

Participants in a metabolomics study are typically required to complete a
questionnaire that confidentially collects information regarding the individuals
age, sex, race/ethnicity, residing state, diet (e.g., vegetarian, vegan, etc.), dietary
restrictions (e.g., no peanuts, no gluten, low-carb, low calorie, no lactose, etc.),
and a list of daily medications or supplements.

3.

Biofluid collection should be done after 12 h of fasting with no fish consumed
for 24 h [75].

4.

Daily supplements and over the counter medications should be stopped at least
24 h prior to collecting the biofluid(s).

5.

Each type of biofluid requires specific and unique collection procedures. For
example, urine specimens are best collected midstream and in the morning, and
can be collected by the participant. Conversely, blood needs to be collected by a
medical professional in a clinical or medical facility. A detailed discussion of
common protocols employed for collecting biofluids from human and animal
cohorts is beyond the scope of this chapter, but have been previously described in
detail [19,53,68,69,76-78].

6.

After collecting a biofluid, the samples should be processed immediately, kept on
ice at all times, and stored at −80 oC.

Preparation of Mammalian Cells

Author Manuscript

1.

Cell culture media and supplements are obtained from commercial vendors (see
Section 2.5). The cell culture media may be supplemented with isotopically
labeled nutrients (e.g., 13C-glucose, 13C-acetate, 15N-ammonium chloride, etc.)
as dictated by the goals of the experiment (see Section 3.7).

2.

Cell culture procedures must follow published guidelines for the cell type to
avoid misidentification and contamination [79].

3.

A minimum target of ten replicate cultures are prepared per group (see Note 8).

8.The number of replicates per group will have a significant impact on the quality of the study and the statistical validity of the
outcomes. In general, it is best to maximize the number of replicates per group, with a typical target of ten replicates per group. A
variety of experimental considerations may impact the number of replicates that are practical for a given study. For example, a large
number of groups may require a reduction in the number of replicates per group. Another consideration is the impact of the number of
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4.

Mammalian cells are typically grown in a 100 mm2 dish with 10 mL of media at
37 °C and 5% percent CO2 in an incubator. Equally distribute replicates from
each group between incubators if more than one incubator is required (see Note
9).

5.

The cells are grown until reaching approximately 80 to 90% confluency.

6.

The drug is added to the cell culture for the treated groups using the dosage
determined from Section 3.3. A blank solvent bolus is added to all non-treatment
groups.

7.

The drug is typically added to the cell culture after 80 to 90% confluency. But,
the drug may also be added at the start of the cell culture or at other time-points
as required.

8.

The cells are harvested after a pre-determined incubation time with the drug.

Preparation of Bacterial Cell Cultures

Author Manuscript
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1.

Perform steps 1–3 from Section 3.5.

2.

The drug is added to the cell culture for the treated groups using the dosage
determined from Section 3.3. A blank solvent bolus is added to all non-treatment
groups.

3.

Typically, the drug is added at the start of the cell culture, but it may be added at
various points along the growth curve depending on the specific goals of the
study or the proposed mechanism of action of the drug.

4.

Start with a 25 mL culture of cells with an OD600 of 0.05 from glycerol frozen
stocks.

5.

For any type of bacterial cell, it is important to obtain a final OD600 of 20 for the
entire culture volume. For example, if the total volume is 20mL, then the
minimum OD600 should be 1.0 per mL. This will ensure that a high quality NMR
spectrum will be obtained from the cell lysates in a reasonable amount of time.

6.

Cell cultures are harvested at a specific time-point of the growth curve (e.g.,
exponential growth, stationary phase, etc.). Important, all cell cultures must be
harvested at the identical phase of the growth curve, not necessarily the same
OD600 value.

7.

All replicate cell cultures are normalized based on the final OD600 value. The
total volume for each individual cell culture is adjusted so that each cell culture
has the same effective OD600 value.

replicates on the quality of the metabolomics samples. Sacrificing quality for a greater number of replicates will not likely lead to a
successful outcome. Conversely, a limited number of replicates < 4 per group will likely provide meaningless results.
9.In order to avoid the introduction of bias, always randomize sample handling steps. If the samples are always processed in the order
of the sample number, then a time-bias will be induced across the entire dataset. Instead, if the order is constantly changed at each
step, the processing time and any impact on the metabolome will be randomized, which in turn will minimize or eliminate any bias.
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Isotopically Labeled Metabolomics Samples
1.

Identify a 13C-, 15N- or other isotopically labeled compound or nutrient to label
the metabolome and act as a tracer. The tracer should be associated with the
metabolic pathway of interest and expected to be affected by the experimental
treatment. 13C6-glucose is a common choice for a tracer since it highlights
central carbon metabolism (e.g., glycolysis and TCA cycle).

2.

The culture media should not contain the selected nutrient or metabolite.

3.

The culture media is supplemented with an appropriate molar concentration of
the tracer metabolite (see Notes 4 and 10). The concentration of the 15N-, or 13Clabeled metabolite needs to be high enough (≥ 1 to 5 μM) to be detected by
NMR. Accordingly, the culture media should be supplemented with
approximately 2.5 to 4 g/L (0.5 to 25 mM) of a major nutrient source like 13C6glucose or ~10–100 mg/L of a targeted metabolite like 13C-D-alanine (~ 1 mM).
Multiple labeled isotopes may be used together if the type of label (13C or 15N)
differs between the compounds.

4.

In general, the isotopically labeled metabolite is added to the culture medium at
the start of the cell culture. Of course, it may be added at different time points to
emphasize a specific cellular processes or timed according to the drug treatment.

Extracting Water Soluble Metabolites from Mammalian Cells

Author Manuscript

Samples should be stored at −80 °C, but, ideally, samples should be immediately analyzed.
All samples should be kept on ice or at 4 °C during the extraction process and/or handling.
There are a few critical aspects to keep note of throughout the process that can affect the
quality of the resultant data (1) speed, (2) consistency, (3) random processing of samples,
and (4) the efficient removal of all biomolecules and cell debris [80]. Quick and prompt
sample processing and preparation are ideal to avoid extended temperature variations,
chances of environmental contamination and degradation of metabolites. For example,
protein degradation due to improper shipping processes may lead to alterations in amino
acid levels in biofluids. Furthermore, metabolites can chemically degrade or transform
within milliseconds due to enzymatic activity, oxidation, chemical instability, or any number
of other chemical processes [81]. Thus, rapid inactivation and removal all macromolecular
cell debris (usually through methanol/ethanol precipitation) that may bind or transform a
metabolite is a necessary step of the protocol (see Note 11).

Author Manuscript

10.The experimental conditions for optimal labeling should be experimentally verified for every cell line or cell type used for a
metabolomics experiment. Factors to consider include the composition of the culture media and the 13C-carbon source (e.g., glucose,
pyruvate or glutamine) that are used for the cell culture. For mammalian cells, a time course experiment should be conducted where
cells are cultured from 1 to 48 h to assess the rate of carbon consumption. For bacterial cells, a time course experiment should be
conducted where cells are cultured for 1 to 3 doubling times to assess the rate of carbon consumption. Examples of media used for
13C-carbon labeling of mammalian cell metabolome are Dulbecco's Modified Eagle Medium (DMEM) and Roswell Park Memorial
Institute (RPMI) media. Examples of media used for 13C-carbon labeling of bacterial cell metabolome are Middlebrook’ Albumin
Dextrose Catalase (MADC) media or M9 minimal media.
11.Removal of proteins and other biomolecules by methanol or ethanol precipitation is preferred over mechanical filtration methods or
the application of Carr–Purcell–Meiboom–Gill (CPMG) NMR T2 filtering techniques. Filtering techniques are known to impart
biologically-irrelevant group differences, due to metabolite-macromolecule binding [87].
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1.

The extraction process for intracellular metabolites begins after the cells have
grown to the desired time point. In addition to the cell extract, the media should
also be analyzed for metabolomics changes as many metabolites get exchanged
or effluxed outside of the cell.

2.

Pre-chill the extraction solvents methanol and methanol:water mixture on dry
ice.

3.

Collect 1 mL of the media and immediately freeze the samples with liquid
nitrogen and store it at −80 °C until ready for NMR sample preparation.

4.

For the cell extracts, wash the cells still attached to the plates twice with 5 mL of
PBS to remove debris. Discard the wash.

5.

Lyse and quench cells with 1 mL of pre-chilled methanol at −20 °C. Incubate
cells at −80 °C for 15 min. This process should detach the cells from the plate.
Confirm cell detachment using a microscope and repeat lyse and quenching step
if necessary.

6.

Using a cell scraper, detach and transfer the cell suspension in methanol to a 2
mL microcentrifuge tube.

7.

Centrifuge the 2 mL microcentrifuge tube for 5 min at 15,000 × g and 4 °C to
pellet the cell debris.

8.

Collect the supernatant and transfer to a new 2 mL microcentrifuge tube. Again,
keep all samples on ice throughout the process.

9.

Perform a second extraction, to improve the overall efficiency. Add 0.5 mL of an
80%/20% mixture of methanol/water prechilled −20 °C to the cell pellet.

10.

Centrifuge the suspension of cell debris with 80%/20% methanol/water for 5 min
at 15,000 × g at 4 °C to pellet the cell debris.

11.

Collect the supernatant and transfer it to the 2 mL microcentrifuge tube
containing the original methanol extract, thereby combining the two extractions.

12.

For a third time extract the pellet by adding 0.5 mL of ice cold water.

13.

Centrifuge the cell suspension for 5 min at 15,000 g at 4 °C to pellet the
remaining cell debris.

14.

Transfer the supernatant to the original microcentrifuge tube. Combine all
extractions together in a 2 mL microcentrifuge tube.

15.

Repeat steps 1 to 14 for each replicate and for each group either in a randomized
fashion or at the same time depending on the total sample number and your
centrifuge capacity (see Note 9).

16.

Use a SpeedVac or a rotary evaporator to remove the methanol, chill the
condenser with liquid nitrogen if using a rotary evaporator.

17.

Following evaporation of the methanol solvent, poke a pin hole using a
thumbtack and flash-freeze the samples in liquid nitrogen.
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18.

Freeze dry the samples using a lyophilizer, the pin hole helps establish low
pressure in each sample tube.

19.

Store samples in a −80 °C freezer or proceed to preparing the NMR samples (see
section 3.11).

Extracting Water Soluble Metabolites from Gram-Negative Bacteria
1.

Spin down the suspension culture at 3200 g at 4°C for 20 min to obtain a pellet.

2.

Aspirate the media, keeping 1 mL of the media for NMR analyses.

3.

Wash the pellet with ice cold PBS before extraction.

4.

Add 1.5 mL of a 1:1 mixture of methanol and water to the pellet and transfer to a
2 mL microcentrifuge tube

5.

Pipet to mix the pellet with a 1:1 mixture of methanol and water prechilled to
−20 °C.

6.

Lyse the cells using a handheld sonicator by pulsing for six 10 s bursts. Take
precautions to avoid any sample heating during the sonication process.

7.

Incubate the microcentrifuge tubes on ice for 2 min to extract the metabolome.

8.

Centrifuge at 1000 × g for 10 min at 4 °C to remove cell debris.

9.

Collect the supernatant (0.75 mL) and transfer to a new 2 mL microcentrifuge
tube.

10.

Repeat the metabolome extraction by adding 0.75 ml of 1:1 mixture of methanol
and water prechilled to −20 °C to the cell pellet.

11.

Repeat steps 6 to 8 and combine the supernatant with the previous extract.

12.

Repeat steps 1 to 11 for all replicate samples and groups (see Note 9).

13.

Use a SpeedVac or a rotary evaporator to remove the methanol.

14.

Flash-freeze the samples in liquid nitrogen.

15.

Remove the water and bring to dryness using a lyophilizer.

16.

Store samples in a −80 °C freezer or proceed to preparing the NMR samples (see
section 3.11).

Extracting Water Soluble Metabolites from Gram-Positive Bacteria

Author Manuscript

1.

Perform steps 1–5 from section 3.9.

2.

Lyse the cells using Matrix B lysing tubes using a FastPrep system. Each sample
is bead beaten for 45s burst at 1200 rpm for three rounds Take precautions to
avoid any sample heating during the process.

3.

Perform steps 7–16 from section 3.9.
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Preparation of NMR samples from cell lysates or tissue extracts
1.

For 1D NMR experiments, lyophilized cell-free lysates or tissue extracts are
suspended in 550 μL of 100% 50 mM D2O phosphate buffer at pH 7.2
(uncorrected, see Note 3) with 50 μM TMSP-d4 as a chemical shift and
concentration reference.

2.

For 2D NMR experiments, lyophilized cell-free lysates or tissue extracts are
suspended in 550 μL of 100% 50 mM D2O phosphate buffer at pH 7.2
(uncorrected, see Note 3) with 500 μM TMSP-d4 as a chemical shift and
concentration reference.

3.

Centrifuge the sample at 14,000 g for 10 min to remove any particulates.

4.

The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ
XLS pipette (see Note 12).

5.

Repeat steps 1 to 4 for each replicate and for each group (see Note 9).

6.

Each sample is added to a 96 well plate SampleJet configuration equilibrated to
4 °C to prevent metabolite degradation (see Fig. 5).

Preparation of NMR Samples from Urine
1.

Thaw the urine samples stored at −80 oC on ice.

2.

Samples are centrifuged at 15,000 × g for 10 min at 4 oC to pellet any
particulates in the sample.

3.

500 μL of urine is transferred into a new Eppendorf tube and mixed with 50 μL
of 50 mM phosphate buffer in 99.8% D2O at pH 7.2 (uncorrected, see Note 3).
50 μM (for 1D 1H NMR) or 500 μM (for 2D NMR) TMSP-d4 are added to each
sample as a chemical shift and concentration reference.

7.

The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ
XLS pipette (see Note 12).

8.

Repeat steps 1 to 7 for each replicate and for each group (see Note 9).

9.

Each sample is added to a 96 well plate SampleJet configuration equilibrated to
4 °C to prevent metabolite degradation (see Fig. 5).

Preparation of NMR Samples from Serum

Author Manuscript

1.

Thaw the serum samples stored at −80 oC on ice.

2.

500 uL of serum sample is transferred into a new Eppendorf tube and mixed with
1 mL of methanol to precipitate proteins.

3.

Samples are centrifuged at 15,000 × g for 10 min at 4 oC.

12.Smaller diameter NMR tubes of 3 mm (160 μL) or 1.7 mm (45 μL) may be needed if the available metabolomics sample is limited.
Filling of these smaller diameter NMR tubes may be improved by a liquid handling robot, such as a Gilson 215 Liquid Handler. In
addition, the NMR acquisition parameters will likely need to be adjusted to account for the lower sensitivity due to the lower number
of nuclei in the samples.
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4.

Transfer the supernatants into new microcentrifuge tubes.

5.

Remove the methanol by rotary evaporation using a SpeedVac.

6.

The samples are flash-frozen in liquid nitrogen and then dried by lyophilization.

7.

The dried samples are reconstituted into 550 μL of 50 mM phosphate buffer in
99.8% D2O at pH 7.2 (uncorrected, see Note 3). 50 μM (for 1D 1H NMR) or 500
μM (for 2D NMR) TMSP-d4 are added to each sample as a chemical shift and
concentration reference.

8.

The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ
XLS pipette (see Note 12).

9.

Repeat steps 1 to 8 for each replicate and for each group (see Note 9).

10.

Each sample is added to a 96 well plate SampleJet configuration equilibrated to
4 °C to prevent metabolite degradation (see Figure 5).

Preparation of NMR Samples from Fecal Matter
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1.

Thaw the fecal samples stored at −80 oC on ice

2.

Weigh 3 to 50 mg of the fecal material in a microcentrifuge tube containing
matrix D type lysing beads.

3.

Add 1 mL of 1:1 water: methanol mixture to extract the metabolome and
precipitate proteins.

4.

Using a FastPrep, bead beat the samples for 30 sec at 1200 rpm thrice.

5.

Centrifuged at 15,000 × g for 10 min at 4 oC.

6.

Collect the supernatants in a separate microcentrifuge tube.

7.

Repeat steps 3–6 to re-extract the pellet and combine both supernatants.

8.

Remove the methanol by rotary evaporation using a SpeedVac and water by
lyophilization

9.

Reconstitute in 550 μL of 50 mM phosphate buffer in 99.8% D2O at pH 7.2
(uncorrected, see Note 3). 50 μM (for 1D NMR) or 500 μM (for 2D NMR) of
TMSP-d4 will be added to each sample as a chemical shift and concentration
reference.

10.

The sample is transferred to a 4” 5 mM SampleJet NMR tube with a RAININ
XLS pipette (see Note 12).

11.

Repeat steps 1 to 10 for each replicate and for each group (see Note 9).

12.

Each sample is added to a 96 well plate SampleJet configuration equilibrated to
4 °C to prevent metabolite degradation (see Fig 5).
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NMR Data Collection
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All NMR experiments are conducted at 298 K using a Bruker AVANCE III HD 700 MHz
spectrometer equipped with a 5 mm quadruple resonance QCI-P cryoprobe (1H, 13C, 15N,
and 31P) with z-axis gradients. An automatic tune and match system (ATM), and a
SampleJet automated sample changer system with Bruker ICON-NMR software were used
to automate the NMR data collection (see Fig. 5).
3.15.1

1D 1H NMR
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1.

Load the NMR metabolomics samples into the SampleJet automated sample
changer system (see Fig. 5 and Note 9). Check that the SampleJet is in the
correct mode (i.e., 5 mm tubes).

2.

Log into an account on the spectrometer workstation and start the Topspin
software.

3.

The first NMR sample is lowered into the magnet using the Bruker command, sx
101, where 101 corresponds to sample one in rack one.

4.

The spectrometer is locked onto the D2O solvent frequency using the Bruker
command, lock D2O (see Note 13).

5.

The NMR sample is shimmed for optimal signal and suppression of the water
signal by typing the Bruker command topshim. This will initiate an automated
gradient shimming procedure, which may take a few min to complete (see Note
13).

6.

The sample is automatically tuned and matched using the ATM system by typing
the Bruker command, atma.

7.

The 90-degree pulse length (μs) is determined by measuring a null spectrum with
an approximate 360-degree pulse using the Bruker zg pulse sequence (see Note
14).

8.

A 1D 1H NMR spectrum is obtained for each sample using a standard excitation
sculpting water suppression pulse program (Bruker zgesgp pulse sequence) that
provides optimal suppression of the residual water signal while maintaining a flat
baseline (see Note 15).

Author Manuscript

13.Topshim requires the sample to contain either a D O or H O solvent. It is advisable to create a shim file with a parameter set that
2
2
produces an optimal set of shims for your sample type. Read in a shim file using the Bruker command rsh and select the appropriate
Topshim shim file. If you are doing this for the first time, complete the command topshim, if you are not satisfied with the shim
performance use command topshim tuneb tunea to obtain an improved set of shims. Write the shim set parameters with the Bruker
command wsh and save it to a new file name for future reference.
14.The 90 degree pulse length is commonly measured by incrementing the P1 pulse in the zg pulse program by 1 μs or smaller
increments; and by plotting the relative peak heights or intensities. A maximum peak height should be observed at the pulse length
corresponding to the 90-degree pulse. Conversely, a minimum or null spectrum should be observed at the pulse length corresponding
to the 360-degree pulse length. In practice, a more accurate measure of the 90-degree pulse is obtained by measuring the 360-degree
pulse length and dividing by four to obtain the 90-degree pulse length. A typical 90-degree pulse length for a metabolomics sample
ranges from approximately 8 μs to 13 μs or longer. Among other factors, the relative salt concentration of the metabolomics sample
affects the 90-degree pulse, in which a higher salt concentration results in a longer 90-degree pulse. Other factors also contribute to the
observed 90-degree pulse, so it is always necessary to experimentally determine the 90-degree pulse for each sample or set of samples.
15.Excitation Sculpting parameters (zgesgp) - 32768 data points (TD), SW = 12.02 ppm, O1P (transmitter offset) = 4.70 ppm, D1= 1
second, NS (number of scans) = 128, DS (dummy/steady state scans) = 16, P1 = 9.5 −13.5 us, SPNAM (shaped pulse for water
suppression) = SINC1.1000 at 26.39 dB or 0.00228 W.
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9.

Typical experimental parameters for a 1D 1H NMR spectrum obtained on a
Bruker 700 MHz spectrometer with a cryoprobe correspond to 128 scans, 16
dummy scans, 32,768 data points, a spectral width of 11,160.7 Hz, and a
relaxation delay of 1.5 (see Note 16).

10.

Automated data collection of the entire set of metabolomics samples is
accomplished using Bruker ICONNMR 5 (see Fig. 5).

11.

The sample filename, solvent, pulse program and temperature parameters are all
defined in Bruker ICONNMR 5 (see Notes 15 to 19).

12.

Collect the 1D 1H NMR spectrum for each replicate and each group (see Note 9).

13.

The data is processed initially with Topspin to verify spectral quality, but
exported for further analysis.

Author Manuscript
Author Manuscript

3.15.2

2D 1H-13C-HSQC NMR (see Note 20)

1.

Follow steps 1 to 7 from section 3.15.1.

2.

Using ICONNMR 5, the sample filename, solvent, pulse program and
temperature parameters are adjusted (see Notes 16 to 19).

3.

The ICONNMR setup is similar to a 1D 1H NMR data collection as shown in
Fig. 5.

4.

A standard 2D 1H-13C-HSQC experiment (Bruker hsqcetgpsisp2 pulse program)
is used to determine the 1H-13C chemical shift correlations for all 13C-labeled
metabolites in the metabolomics sample (see Note 20).

5.

Typical experimental parameters for a 2D 1H-13C-HSQC NMR spectrum
obtained on a Bruker 700 MHz spectrometer with a cryoprobe correspond to 128
scans, 32 dummy scans, and a 1.0 s relaxation delay. The spectrum is collected
with 2 K data points and a spectrum width of 4,734 Hz in the direct dimension
and 64 data points and a spectrum width of 18,864 Hz in the indirect dimension
(see Note 21).
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16.The NMR data acquisition parameters need to be adjusted to compensate for differences in the field strength and sensitivity of the
NMR spectrometer actually used for the data collection. Specifically, the number of scans, the number of data points, the sweep-width
(13.79 ppm, 1H frequency range) and the frequency-offset (centered on water peak at 4.70 ppm) need to be adjusted according to the
type and configuration of the NMR spectrometer used for the study.
19.Parameters to check before you queue experiments in ICONNMR for 1D 1H NMR are: number of scans ns, number of dummy
scans ds, 90 degree pulse p1, delay d1, sweep width sw, receiver gain rg, experiment temperature te, and automation setup aunm. We
recommend using au_zgonly as the automation setup. This will collect all samples at the same receiver gain, which will avoid peak
intensity variation across the dataset.
20.NMR metabolomics studies are beginning to make use of HMBC, TOCSY, HSQC-TOCSY, 2D J-Resolved spectra, or other
experiments along with the traditional 2D 1H-13C HSQC approach. Heteronuclear isotope labels like 15N, 31P and other isotopelabeled metabolites may be detected in addition to 1H- and 13C-labeled metabolites [93]. Accordingly, experimental parameters, data
processing and preprocessing methods, and data analysis techniques all need to be adjusted to accommodate the specifics of each
NMR experiment.
21.2D 1H-13C-HSQC parameters (hsqcetgpsisp2) - 1024 data point in F2 and F1, Non-Uniform Sampling at 25%, O1P = 4.7 ppm,
O2P (offset for 13C) = 75 ppm, NS = 64, DS = 16, d1 =2, P1 = 10 − 13 μs depending on salinity, CPDPRG2 = garp (decoupling
program), PCPD2 = 55 μs at PLW12 = 4.09 W.
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6.

Implementation of fast NMR methods that includes non-uniform sampling
significantly decreases data acquisition time and/or increases spectral resolution,
but may introduce artifacts (see Note 22).

7.

Collect the 2D 1H-13C-HSQC NMR spectrum for each replicate and each group
(see Note 9).

8.

Process the data initially with Topspin to verify spectral quality, but exported for
further analysis (see Figs. 6 and 7).

NMR Data Processing (see Note 23)
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All NMR data is processed and analyzed with our MVAPACK software [57], our PCA/PLSDA utilities [58], NMRPipe [59], and NMRViewJ [60]. See example processing scripts at
http://bionmr.unl.edu/wiki/Scripts. Please see the NMRPipe and nmrDraw tutorial (https://
spin.niddk.nih.gov/NMRPipe/doc1/) and NMRViewJ documentation (http://docs.nmrfx.org/)
for more details.
3.16.1

1D 1H NMR (see Figs. 6 and 8)

1.

Apply a 1.0-Hz exponential apodization function to the FID.

2.

Fourier transform the FID.

3.

The resulting NMR spectrum is automatically simultaneously phased corrected
and normalized with the phase-scatter correction algorithm [82].

4.

Reference the NMR spectrum to the peak of TMSP-d4 (0.0 ppm).

5.

Remove the noise and solvent regions manually.
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3.16.2

2D 1H-13C-HSQC NMR (see Figs. 7 and 8)

1.

Apply a sine-bell apodization function to the t2 dimension.

2.

Zero fill the t2 dimension three times.

3.

Fourier transform he t2 dimension, manually phase correct, and delete the
imaginary data.

4.

Transpose the data matrix.

5.

Apply a sine-bell apodization function to the t1 dimension.

6.

Zero fill the t1 dimension three times.

Author Manuscript

22.Non-uniform sampling of 2D 1H 13C HSQC data can be performed on metabolomics samples albeit with some caution. From our
experience we recommend no lower than 20% sparsity using the burst augmented scheduler available on http://bionmr.unl.edu/dgsgensched.php. Download the sampling schedules as a text file for Topspin. Similarly, processing scripts need to be adapted for NUS
datasets and a quick guide to that can be found online at http://bionmr.unl.edu/wiki/NUS.
23.A minimalistic approach to the processing of NMR data is optimal for a metabolomics analysis based on multivariate statistics
models such as PCA and OPLS. The resulting multivariate statistical model is dependent on the choice of processing and
preprocessing protocols. Baseline corrections and alignment, type of weighting (apodization) function, the type of spectral alignment
or referencing, the resulting phase correction or phase correction algorithm, the number of zero-fills or the application of linearprediction, or any other data manipulation method will affect the outcome of the statistical model. Accordingly, it is best to avoid data
processing steps since it is difficult to ascertain if the data processing induced a biologically-irrelevant bias to the data or improved the
model.
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7.

Fourier transform the t1 dimension and phase correct manually.

8.

Reference the NMR spectrum in both dimensions to the peak of TMSP-d4 (0.0
ppm).

NMR Data Preprocessing for Multivariate Modeling
To obtain an accurate and reliable multivariate statistical model, it is essential that the data
set is properly preprocessed to remove normal systematic variations resulting from
biological variability, instrument instability, and inconsistency in sample handling and
preparation. Key preprocessing steps include: (1) alignment, (2) normalization, (3) binning,
and (4) scaling, which is illustrated in Fig. 9. All NMR datasets are processed with our
MVAPACK software [82] and our PCA/PLS-DA utilities [58]. See example MVAPACK
scripts at http://bionmr.unl.edu/wiki/Scripts.
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3.17.1

1D 1H NMR

1.

Spectra may first be normalized based on either the total cell count or the total
protein concentration using the BCA (Bicinchoninic Acid) protein estimation
assay using parallel dishes treated similarly.

2.

Normalize the spectra with the PSC algorithm [82].

3.

Align and/or bin the spectra. For principal component analysis (PCA), use the
following parameters:

Author Manuscript

4.

a.

Globally align the spectral data to the peak of TMSP-d4 at 0.0 ppm.

b.

Regionally align the spectral data using the icoshift algorithm [83].

c.

Bin the spectral data using the adaptive, intelligent binning algorithm
[84].

For orthogonal projection to latent structures (OPLS), use the following
parameters:
a.

Globally align the spectral data to the peak of TMSP-d4 at 0.0 ppm.

b.

Regionally align the spectral data using the icoshift algorithm [83].

c.

The spectral data are not binned. Instead, use the full-resolution spectral
data to build the model.
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5.

Manually remove the solvent peaks and noise regions.

6.

Scale the data set using Pareto scaling.

7.

Generate the PCA or OPLS model from the data matrix.

3.17.2

2D 1H-13C-HSQC NMR

1.

Spectra may first be normalized based on either the total cell count or the total
protein concentration as explained above.

2.

Normalize the spectral data using standard normal variate normalization.
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3.

Bin the spectral data using a generalized adaptive, intelligentbinning algorithm
[84].

4.

Pareto scale the data.

5.

Generate a PCA or OPLS model from the data matrix.

Statistical Analysis
Data sets are analyzed with our MVAPACK software [57], our PCA/PLS-DA utilities [58],
and R [85]. See example MVAPACK and R scripts at http://bionmr.unl.edu/wiki/Scripts.
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Improper application of statistical methods is a serious issue in the field of metabolomics,
which results from some common misconceptions. For example, validation of supervised
multivariate statistical methods are routinely lacking. Instead, supervised OPLS and PLS
models need to be validated using a cross validation score like CV-ANOVA [86] and/or
response permutation testing [87]. R2 and Q2 values, from these supervised models provide
a measure of model fitness from the original data and a measure of consistency between the
original and predicted data. R2 and Q2 values do not provide for model validation without a
proper standard of comparison.
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Metabolomics data sets are often described using PCA or PLS/ OPLS models. It is important
to note that PCA finds the largest source of variance in the dataset irrespective of the intent
of the study. Separation of clusters observed in a PCA model may not have anything to do
with a drug treatment if there are other major sources of variance in the data. Thus, a
loadings plot generated from a PCA model represents all of the variation in the data set, not
just the expected changes induced by the drug treatment. Supervised methods, like PLS and
OPLS, address this issue by aggressively forcing group separation based on the defined
group membership. So, by design, group separation is almost always achieved in a
supervised model and should not be interpreted as a novel discovery in itself. Again, group
separation may occur irrespective of the validity of the model. This happens because PLS
and OPLS models are easily over-fitted, especially for metabolomics data sets since the
number of variables (e.g., metabolites) are typically larger than the number of replicates.
This forced separation of groups also contributes to a common misconception in the
metabolomics community, the incorrect belief that OPLS or PLS out-performs PCA in
identifying group separation and the underlying dataset variances. Remember, PCA finds the
largest source of variance in the dataset, so if there is no variance in a PCA model, smaller
group-specific variations are also not present. Thus, if PCA fails to identify group separation
it is unlikely that PLS or OPLS will yield a valid model despite the appearance of group
separation [87]. Simply, PCA, PLS and OPLS generate different models by extracting
different information to achieve different goals.
PLS and OPLS appear to provide a similar model. In fact, a comparison of PLS and OPLS
scores plots generated from the same data set may suggest the only difference is a relative
rotation of the group-defined ellipses. Nevertheless, this apparently subtle change highlights
a critical difference. PLS intermingles both group-independent and group dependent
variance; whereas, OPLS places group-independent variance (e.g., confounding factors such
as differences in diet, age, race, etc.) orthogonal to group-dependent variance. Therefore, a
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metabolite identified as a major contributor to an OPLS model is strictly the result of the
defined group difference. Accordingly, we strongly recommend using OPLS instead of PLS.
3.18.1

Univariate Analysis

1.

Determine relative metabolite abundances from NMR spectral peak heights
and/or peak volumes (see Fig. 8).

2.

Normalize relative metabolite abundances on a per spectrum basis. One common
approach is to convert the absolute peak intensities (arbitrary units) to a Z-score:
Z=

Ii − Ī
σ

(1)
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where Ī is the average peak intensity for the spectrum, Ii is the intensity of peak i,
and σ is the standard deviation of peak intensities. Peak intensities may also be
normalized to the total number of cells, to the total protein concentration (see
section 3.17.1), to the average spectral noise, or to an internal standard (see Note
24). Relative metabolite abundances may also be converted to fold-changes:
F=

Ii
Io

(2)

where Ii is the normalized peak intensity of metabolite i from a treated spectrum
and Io is the normalized peak intensity of metabolite i from the control or
untreated spectrum.
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3.

A standard Student’s t-test is commonly used to determine statistical significance
only for a pairwise comparison of metabolite changes based on either foldchanges or normalized peak intensities (see Note 25). A statistically significant
difference is typically identified by a p-value < 0.05 (see Fig. 8).

4.

A Student’s t-test is insufficient for the multiple comparisons that are common to
a metabolomics study [87,88]. In order to identify the set of metabolites that
exhibit a statistically significant change, a multiple hypothesis test correction
method such as a Benjamini-Hochberg [89] or a Bonferroni [90] correction must
be applied (see Note 25 and 26).
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24.For NMR, relative peak intensities are averaged across all replicates per group and for each NMR peak assigned to the metabolite.
Most metabolites will have more than one peak in an NMR spectrum and commonly all NMR peaks are incorporated into an average
relative peak intensity. If a metabolite is differentially labeled due to contributions from different pathways, it is then appropriate to
show single resonances for the metabolite. NMR peaks may need to be scaled by the number of attached hydrogens, since peak
intensity is proportional to the number of nuclei.
25.There are a wide variety of statistical tests available to analyze the data. Some examples are the Mann–Whitney U test [94],
Welch’s t-test [95], Hotelling’s t-squared statistic [96], and one-way analysis of variance [87], among others. The proper choice of a
statistical test depends on several factors. A good introduction to what dictates choice of statistical tests can be found in A Biologist’s
Guide To Statistical Thinking And Analysis [95].
26.In effect, the uncertainty in each pairwise comparison (as determined by the Student’s t-test) is compounded with the addition of
each metabolite to a set. The actual p value for a set of metabolites is defined as:
p = 1‐(1‐α)m
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5.
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3.18.2
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3.19

A heat-map with hierarchical clustering is commonly generated from the foldchanges or normalized peak intensities using R (see example R script at http://
bionmr.unl.edu/wiki/Scripts). The heat-map may contain relative metabolite
abundances for each individual replicate in the study or simply the replicateaverages for each group (see Note 27).
Multivariate Analysis

1.

Generate a PCA and or OPLS model from the data matrix.

2.

Fractions of explained variation (R2X and R2Y) are computed during PCA or
OPLS model training.

3.

Internally cross-validate the PCA or OPLS model using seven-fold Monte Carlo
cross-validation [91] to compute Q2 values (see Note 28).

4.

For an OPLS model, compare the Q2 value against a distribution of null model
Q2 values in 1000 rounds of response permutation testing [87]. Group
membership is randomly reassigned to generate the set of null models. A p-value
is calculated from a comparison of the true Q2 value to the set of null model Q2
values (see Note 28).

5.

Further validate the model using CV-ANOVA significance testing, which is used
to calculate another model p-value [86] (see Note 28).

6.

Scores plots (see Figure 6), back-scaled loadings plots (see Figure 8), S-plots
and/or SUS-plots are often generated from OPLS models.

7.

PCA/PLS-DA utilities [58] are used to define group membership by drawing an
ellipse per group onto the scores plots (see Figs. 6 and 7). Each ellipse
corresponds to 95% confidence interval for a normal distribution. The PCA/PLSDA utilities also generate a metabolomics tree diagram that identifies the
statistical significance (p-value and/or bootstrap value) and the relative similarity
of each group in the scores plot (see Fig. 6). The p-value or bootstrap number
from the pairwise comparison is labeled at each node in the tree.

Data Analysis - Metabolite Assignment from 1D 1H NMR Data
NMR data are analyzed with NMRPipe [59], NMRViewJ [60], and Chenomx. See example
scripts at http://bionmr.unl.edu/wiki/Scripts. Please see the NMRPipe and nmrDraw tutorial
(https://spin.niddk.nih.gov/NMRPipe/doc1/) and NMRViewJ documentation (http://
docs.nmrfx.org/) for more details.
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where m is the number of hypotheses (metabolites) and α is typically defined as 0.05. Accordingly, a set of 10 metabolites becomes an
insignificant p = 0.401 even though each individual metabolite is statistically significant based on a pairwise Student’s t-test with a p <
0.05.
27.It is more informative to display all replicates from each group in the heatmap. Hierarchical clustering of each replicate is
indicative of the relative group separation and provides further confirmation of an observed group separation from a PCA, PLS or
OPLS scores plot.
28.Typical R2 values > Q2 values, and Q2 values > 0.4. While p-values < 0.05 are typically acceptable for a supervised PLS-DA or
OPLS model. Usually, high quality PLS/OPLS models from metabolomics data sets yield p-values << 0.001.
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1.

Perform the identification of metabolites in a 1D 1H NMR spectrum with
software programs such as Chenomx. Chenomx matches the experimental 1D 1H
NMR spectrum to a database of 1D 1H NMR spectra of known metabolites.
Chenomx attempts to explain or describe the experimental NMR spectrum by
combining or summing as many of the individual reference metabolite NMR
spectra as needed. In addition to metabolite identification, Chenomx also
provides an estimate of the metabolite concentration (see Note 29).

2.

Upload the 1D 1H NMR spectrum for processing. The NMR spectra can be batch
processed or processed one at a time.

3.

Phase the 1D 1H NMR spectrum.

4.

Calibrate and reference the 1D 1H NMR spectrum to TMSP-d4, using the known
concentration of TMSP-d4.

5.

Send the properly phased and calibrated 1D 1H NMR spectrum to the Chenomx
profiler where the spectrum is compared against the metabolite library.

6.

Chenomx will overlay a 1D 1H NMR reference spectrum for each metabolite
identified in the experimental 1D 1H NMR spectrum. The spectral overlay needs
to be manually adjusted to optimize the alignment of the experimental 1D 1H
NMR spectrum with the reference spectrum. Fig. 8 shows an example of a
labeled 1D 1H NMR spectrum.

Data Analysis - Metabolite Assignment from 2D 1H-13C-HSQC NMR Data
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NMR data are analyzed with NMRPipe [59] and NMRViewJ [60]. See example scripts at
http://bionmr.unl.edu/wiki/Scripts. Please see the NMRPipe and nmrDraw tutorial (https://
spin.niddk.nih.gov/NMRPipe/doc1/) and NMRViewJ documentation (http://docs.nmrfx.org/)
for more details.
3.20.1

NMRPipe Processing to Obtain. ft2 and .nv Files.
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1.

The data files from ICONNMR can be used directly by NMRPipe to process the
2D 1H-13C-HSQC spectra.

2.

On a Linux workstation, open a terminal and go to the directory that contains the
NMR data. Type bruker to start the NMRpipe software.

3.

Read in the experimental parameters file by clicking Read Parameters and verify
that all the parameters have been correctly updated. Confirm that the mode of
data collection has been set to echo-antiecho if the NMR spectrum was collected
with the hsqcetgpsisp2 pulse program.

4.

Click Update Script to save an NMRPipe processing script fid.com file in the
working directory.

29.NMR field strength and sample pH are important aspects of any chemical shift database matching. Thus, we strongly recommend
performing a chemical shift match with the correct database (e.g., same NMR field strength and pH) while using Chenomx or similar
software.
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5.

Type ./fid.com to start the NMRPipe processing script.

6.

When the NMRPipe processing has finished, type nmrDraw to view the
processed NMR spectrum. Please see the NMRPipe and nmrDraw tutorial
(https://spin.niddk.nih.gov/NMRPipe/doc1/) for detailed instructions.

7.

Phase the NMR spectrum in NMRpipe and note the p0 and p1 values for both the
1H and 13C dimensions.

8.

Edit the NMRPipe processing script hsqcproc.com and replace the parameters
associated with the NMRPipe phase correction command, ps, with the p0 and p1
values obtained from step 7.

9.

Type ./hsqcproc.com to start the NMRPipe processing script

10.

Repeat steps 3 to 9 for each 2D 1H-13C-HSQC NMR spectrum in the dataset.
This produces a set .ft2 files. One .ft2 file is created for each 2D 1H-13C-HSQC
NMR spectrum collected for each replicate from each group.

11.

Copy all of the .ft2 files into a new folder and use the NMRPipe script
addnmr.com to generate NMRviewJ files from the .ft2 files. A .nv file will be
generated for each individual spectrum (.ft2 file) with a numerically incremented
root name of “Final_”. In addition, the script will combine all of the NMR
spectra together into a single file called results.nv. The script will also generate
the text file, rate.txt, which lists all of the individual .nv files (Final_).

3.20.2 Peak Picking and Peak Integration of 2D 1H-13C-HSQC Spectra in
NMRviewJ
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1.

Type nmrviewj to start NMRviewJ. Refer to NMRViewJ documentation (http://
docs.nmrfx.org/) for more details.

2.

From the Dataset toolbar in the main window, use the Open and Draw Datasets
function to select the result.nv file.

3.

Right click and select attributes to open the attributes window.

4.

In the attributes window, select the PeakPick tab.

5.

In the blank Lists field in the attribute window, type a filename (i.e., lists) for the
new peak pick list. Click the Pick button. The software will automatically peak
pick the displayed spectrum and populate lists with the peak ID number,
chemical shifts, and intensity.

6.

Choose Show Peak Table from the Peak toolbar on the main window. A peak
table window will open that lists the peak ID, peak intensity and the peak
chemical shifts.

7.

Manually edit the peak list and remove solvent peaks, noise peaks or other
spectral artefacts. Peaks are deleted from the peak table by using the delete
function in the PeakPick tab in the attributes window along with the spectrum
display window. In the spectrum display window, use the mouse to position the
two cursors around any peak or spectral region to form a box. Then, click the
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Delete button under the PeakPick tab in the attributes window to remove the
peak(s).
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8.

After the peak table has been completely edited, on the peak table window
choose the Edit tab and select Compress & Degap. Answer yes to the pop-up
question. This will finalize changes to the peak list and prevent any further edits.

9.

On the peak table window choose the Edit tab and then select Save Table. A file
browser window will open in order to choose a name and location to save the
new peak list file. The saved peak pick file can be viewed and edited in Excel.

10.

In order to obtain peak intensities across the entire set of NMR spectra in the
dataset, click on the Analysis tab on the main window and select Rate Analysis.
A set-up window for the Rate Analysis will open.

11.

In the Rate Analysis set-up window:
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a.

Set the Prefix for matrix numbers field to Final_

b.

Set the Peaklist field to lists (defined in section 3.20.2 step 5).

c.

Make sure Auto fit is checked.

d.

Use all other default settings.

e.

Click Load time file.

f.

In the file browser window, select rate.txt (created in section 3.20.1 step
11).

g.

Click Measure All. The software automatically populates the table in
the Rate Analysis set-up window with all of the peak intensities across
the entire NMR dataset.

h.

Click Save Table. In the file browser window, save the peak intensities
table to a new filename (i.e., intensities).

12.

The peak list (i.e., list) and the peak intensities (i.e., intensities) files are merged
in Microsoft Excel using the common peak ID column. The ppm1 (1H ppm) and
ppm2 (13C ppm) columns are added to the peak intensities columns to generate a
complete matrix of NMR peaks and intensities across the entire data set.

13.

The merged Excel file is saved to a new filename.

3.20.3

Metabolite Assignments from 2D 1H-13C-HSQC Peak Lists
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1.

The complete list of peaks obtained from the NMRviewJ analyses is searched
using NMR metabolomics databases such as HMDB [62], BMRB [63], or other
databases (see Note 30).

2.

On the HMDB homepage, choose the Search tab and select 2D NMR Search.

30.BMRB, HMDB and other such databases operate in a similar fashion. Simply upload a peak list with a set of chemical shift
tolerances and obtain a list of potential matches.
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3.

From the Spectra Library pull-down menu, choose 13C HSQC.

4.

Cut and paste the 2D 1H-13C-HSQC peak lists into the Peak List field. One set of
1H and 13C chemical shifts, respectively, per line. Chemical shift values should
only be separated by white space.

5.

Set the 1H chemical shift error tolerance to 0.05 ppm (X-axis Peak Tolerance ±
field) and the 13C chemical shift error tolerance to 0.10 ppm (Y-axis Peak
Tolerance ± field).

6.

Click the Search button. Depending on the size of the peak list, the software will
return a ranked-order list of possible metabolites based on the number of
chemical shift matches to reference spectrum.

7.

Manually curate the list of potential metabolite assignments based on the number
of chemical shift assignments, the quality of the spectral overlap (i.e., chemical
shift match), number of other metabolites in the same metabolic pathway, and the
biological system (i.e., is it a reasonable or possible metabolite for the organism),

8.

Obtain additional NMR (e.g., HMBC, HSQC-TOCSY) and/or MS spectral data
to confirm or refute the assignment.

9.

An assigned 2D 1H-13C-HSQC spectrum is shown in Fig. 8.
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Fig. 1.

A schematic diagram outlines the overall drug discovery process and highlights the role of
NMR and NMR-based metabolomics at every step in the process. Traditional drug discovery
roles for NMR are boxed in grey, while NMR metabolomics applications are boxed in green.
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Fig 2.
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Cartoon illustrations of hypothetical PCA scores plot for the following scenarios (a) inactive
compound, (b) active and selective inhibitor, (c) active, nonselective inhibition of target and
secondary protein, and (d) active, nonselective preferential inhibition of secondary protein.
Labels correspond to: wild-type cells (wt) and mutant cells (mut). Reproduced with
permission from Ref 51. Copyright © 2006 American Chemical Society.
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Fig. 3.
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(a) A summary of the design and planning steps in a typical metabolomics-based drug
discovery project. (b) A workflow for a typical cell-based NMR metabolomics experiment
focused on understanding the mechanism of action for a chemical lead.
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Fig. 4.

An example bacterial growth curve for a cell line treated with a drug at an OD600 of 0.6. The
cellular metabolome should be extracted during the log phase, which captures the majority
of metabolic variations.
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Fig 5.
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High-throughput sample preparation and data collection. (a) Images illustrating the loading
of replicate metabolomics samples into the 96 well plate SampleJet configuration. (b)
ICONNMR screenshots illustrating the stepwise workflow for setting-up a high-throughput
1D 1H NMR metabolomics screen.
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Fig. 6.
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A representative example of bacterial cells treated with existing drug therapies to decipher
the in vivo mechanism of action of unknown drugs using 1H NMR based metabolomics. (a)
2D OPLS-DA scores plot demonstrating the clustering pattern for 12 antibiotics with known
biological targets and three compounds of unknown in vivo activity: untreated cells (■
black), chloramphenicol (♦ teal), ciprofloxacin (♦ orange), gentamicin (♦ pink), kanamycin
(♦ purple), rifampicin (♦ red ), streptomycin (♦ yellow), ethambutol (▼ green),
ethionamide (▼ blue), isoniazid (▼ pink), ampicillin (▲ red ), D-cycloserine (▲ purple),
vancomycin (▲ orange), amiodorone (● purple), chlorprothixene (● green), and
clofazimine (● red) treated M. smegmatis cells. The ellipses correspond to the 95%
confidence limits from a normal distribution for each cluster. The untreated M. smegmatis
cells (■ black) were designated the control class, and the remainder of the cells was
designated as treated. The OPLS-DA used one predictive component and six orthogonal
components to yield a R2X of 0.715, R2Y of 0.803, and Q2 of 0.671. (b) Metabolomics tree
diagram was determined from the OPLS-DA scores plot. The coloring scheme and
associated symbol for each compound in the tree diagram correlates with colored symbols in
the OPLS-DA scores plot. The bootstrap numbers for each node are indicated on the tree
diagram. Reproduced with permission from Ref 52. Copyright © 2012 American Chemical
Society.
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Fig. 7.

Author Manuscript

Metabolomics analysis on the effect of (R,R′)-MNF in PANC-1 cells. (a) PCA scores
resulting from modeling of the 1D 1H NMR data matrix from untreated PANC-1 cells (open
symbols) and PANC-1 cells treated with 0.5 μM (R,R′)-MNF (gray symbols) or 1 μM (R,R
′)-MNF (black symbols). A statistically significant degree of separation is observed between
treated and untreated groups. The ellipses correspond to 95% confidence intervals for a
normal distribution. Each principal component is labeled with the corresponding R2 and Q2
values. (b) Bar graph of 1D 1H NMR peak intensities (relative metabolite concentrations)
resulting from the analysis of PANC-1 cellular extracts after a 1 h incubation with 0.5 μM
(hatched bars) or 1 μM (filled bars) of (R,R′)-MNF versus untreated cells (open bars).
Metabolites were identified from the back-scaled loadings plots as the major contributors to
the group separations in the OPLS models. Benjamini-Hochberg corrected Student's t-test pvalues from pairwise comparisons are indicated. An asterisk indicates significance between
the control and 1 μM of (R,R′)-MNF while an asterisk with underlying bar indicates

Methods Mol Biol. Author manuscript; available in PMC 2020 February 17.

Bhinderwala and Powers

Page 44

Author Manuscript

significance between the control and both treated groups. (c) Metabolic pathway analysis of
the identified metabolites found in the 1D 1H NMR spectra of the PANC-1 extracts after 1 h
incubation with 0.5 μM or 1 μM of (R,R′)-MNF. Each circle represents a matched pathway
and is colored according to its p values from the pathway enrichment analysis. Statistically
significant pathways (p < 0.05) are labeled with their common name. (d and e) Targeted
metabolomics on the effect of 1 μM (R,R′)-MNF on intracellular concentrations of
carnitine, 1-lactate, and 3-hydroxybutyrate in PANC-1 cells (d) as well as MCF-7 and MDAMD-321 breast tumor cells (e). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. Reproduced with
permission from M. Bernier, J. Catazaro, N. S. Singh, Q. Shi. M. Wang, Q. Yang, A.
Wnorowski, K. Jozwiak, R. Powers, and I. W. Wainer* (2017) "GPR55 Receptor
Antagonists Decrease Glycolytic Activity in PANC-1 Pancreatic Cancer Cell Lines and
Tumor Xenografts", International Journal of Cancer, 141(10):2131-2142 Copyright © 2017
John Wiley and Sons.
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Examples of a typical (a) 2D 1H-13C HSQC spectrum and (b) 2D 1H-1H TOCSY spectrum
acquired from bacterial cells. Reproduced with permission from Zhang, B.; Halouska, S.;
Schiaffo, C. E.; Sadykov, M. R.; Somerville, G. A.; Powers, R. NMR analysis of a stress
response metabolic signaling network. J. Proteome Res., 2011, 10, 3743- 3754. Copyright ©
2011 American Chemical Society. (c) 1D 1H NMR spectrum acquired from bacterial cells.
Reproduced with permission from S. Halouska, R. J. Fenton, D. K. Zinniel, D. D. Marshall,
R. G. Barletta* and R. Powers* (2014) "Metabolomics Analysis Identifies D-Alanine-Dalanine Ligase as the Primary Lethal Target of D-cycloserine in Mycobacteria", J. Proteome
Res., 13(2):1065-1076. Copyright © 2014, American Chemical Society. (d) Back-scaled
loadings plot for 1D 1H NMR spectra showing 15 different metabolites that vary between
groups. Reproduced with permission from Ref 15. Copyright © 2017 American Society for
Microbiology. (e) Heatmap showing differences between the vancomycin-susceptible
Staphylococcus aureus (VSSA) strains and S. aureus with intermediate-level resistance to
vancomycin (VISA) metabolome. The heatmap was generated by using 2D 1H-13C HSQC
NMR spectrum-normalized peak intensities of the VSSA or VISA strain, and hierarchical
clustering is depicted by the dendrogram. The color scale ranges from 0 (red; less intense) to
1 (green; intense). Statistical significance is denoted by a single asterisk if determined using
Student’s t test at the 95% confidence level or by two asterisks if determined by Student’s t
test with a Bonferroni correction for multiple-hypothesis testing. Reproduced with
permission from Ref 15. Copyright © 2017 American Society for Microbiology.
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Fig. 9.

Example of an MVAPACK processing script for a 1D 1H NMR dataset. The numbered steps
in the flow diagram correspond to the numbered lines in the processing script.

Methods Mol Biol. Author manuscript; available in PMC 2020 February 17.

Bhinderwala and Powers

Page 47

Table 1:

Author Manuscript

A list of typical exclusion criteria for a metabolomics clinical study
Exclusion Criteria
•

Acute illness within 2 weeks

•

Comorbidity (e.g., chronic lung disease, depression, etc.)

•

Excessive intake of alcohol

•

Obesity

•

Pregnant women or menstruating women

•

Recreational drug use

•

Risk of transmitting disease through urine (e.g., hepatitis B or C)

•

Significant abnormalities in clinical chemistry of hematology

•

Smoker
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